UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $906,000 in Pharvaris (NASDAQ:PHVS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Pharvaris (NASDAQ:PHVS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 48,896 shares of the company’s stock, valued at approximately $906,000.

Several other hedge funds have also bought and sold shares of PHVS. Sofinnova Investments Inc. raised its position in Pharvaris by 2.9% during the second quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company’s stock valued at $11,309,000 after purchasing an additional 16,862 shares in the last quarter. Deerfield Management Company L.P. Series C increased its position in shares of Pharvaris by 31.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock valued at $26,269,000 after purchasing an additional 335,687 shares during the last quarter. Finally, Novo Holdings A S raised its holdings in shares of Pharvaris by 47.7% during the 2nd quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock valued at $32,430,000 after buying an additional 556,970 shares in the last quarter.

Pharvaris Trading Up 2.8 %

Shares of NASDAQ:PHVS opened at $19.01 on Friday. The stock has a market capitalization of $605.28 million, a P/E ratio of -6.79 and a beta of -3.17. The stock’s 50-day moving average price is $21.22 and its 200-day moving average price is $19.22. Pharvaris has a 12-month low of $15.37 and a 12-month high of $33.00.

Analysts Set New Price Targets

Separately, Oppenheimer upped their target price on Pharvaris from $38.00 to $42.00 and gave the stock an “outperform” rating in a research note on Friday, September 6th.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.